Clinical study of acute promyelocytic leukemia with expression of BCR 3 isoform of PML-RARa fusion gene
10.3969/j.issn.1671-8348.2013.28.019
- VernacularTitle:PML-RARa融合基因BCR3亚型急性早幼粒细胞白血病的临床研究
- Author:
Xin WANG
;
Lin LIU
;
Jianbin CHEN
;
Jianyu WANG
;
Qin XIAO
- Publication Type:Journal Article
- Keywords:
leukemia,promyelocytic,acute;
all-trans-retinoic acid;
arsenic trioxide;
PML-RARa fusion gene
- From:
Chongqing Medicine
2013;(28):3382-3384,3387
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the efficacy of combination therapy with all-trans-retinoic acid (ATRA ) and arsenic trioxide (ATO) in treating patients with acute promyelocytic leukemia (APL) .Methods A retrospective study was conducted to evaluate the efficacy of combining ATO with ATRA based induction therapy ,followed by 3 courses of consolidation chemotherapy and 2-year sequential ATO/ATRA maintenance therapy in newly diagnosed APL ,and the efficacy between high risk group and low/inter-mediate risk group ,also between different PML-RARa isoform sub-group were compared .Results In high risk group and low/in-termediate risk group ,the complete remission(CR)rates were 70 .0% and 96 .9% (P=0 .04) ,respectively ;the 3 years overall sur-vival rates(OS) and disease free survival rates (DFS) were(70 .0 ± 14 .5)% ,(96 .9 ± 3 .1)% ,P= 0 .01 and(66 .7% ± 19 .2)% , (93 .8 ± 6 .1)% ,P=0 .08 ,respectively .In BCR1 group and BCR3 group ,the CR were 78 .6% and 95 .6% (P=0 .14) ,respectively ;the rates of 3 years OS and DFS were(95 .7 ± 4 .3)% ,(78 .6 ± 11 .0)% ,P=0 .18 ,and(92 .9 ± 6 .9)% ,(87 .5 ± 11 .7)% ,P=0 .24 , respectively .Conclusion The results indicate that ATO based first-line protocol is highly effective for treatment of newly diagnosed APL ,especially for the PML-RARa BCR3 isoform APL .
